Bharat Parenterals Ltd

Bharat Parenterals Ltd

₹ 1,457 -1.98%
24 May - close price
About

Bharat Parenterals Ltd. is a Gujarat based pharmaceutical company producing general and B-lactum group of drugs as well as antiretroviral drugs. [1]

Key Points

Product Portfolio
The Co has a portfolio of over 500 formulations. It produces pharmaceuticals across categories such as B-LACTAM Antibiotics, Anti Retroviral, Cephalosporins Antibiotics, Antiprotozoal / Anthelmintic Respiratory, Antiallergic, Cleansing Agents /Skin Infections, Cardiovascular System, Anti Diabitic, Anti Fungal etc. [1]

  • Market Cap 842 Cr.
  • Current Price 1,457
  • High / Low 1,825 / 330
  • Stock P/E 37.2
  • Book Value 370
  • Dividend Yield 0.05 %
  • ROCE 12.7 %
  • ROE 11.2 %
  • Face Value 10.0

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 3.94 times its book value
  • The company has delivered a poor sales growth of 2.96% over past five years.
  • Company has a low return on equity of 12.0% over last 3 years.
  • Earnings include an other income of Rs.12.0 Cr.
  • Dividend payout has been low at 1.45% of profits over last 3 years
  • Company has high debtors of 201 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
40.62 60.84 60.40 38.46 52.31 26.09 81.90 59.02 50.97 69.91 59.81 58.80 65.64
37.89 50.14 50.21 35.62 47.77 24.16 72.56 55.51 44.38 58.42 53.38 52.02 61.90
Operating Profit 2.73 10.70 10.19 2.84 4.54 1.93 9.34 3.51 6.59 11.49 6.43 6.78 3.74
OPM % 6.72% 17.59% 16.87% 7.38% 8.68% 7.40% 11.40% 5.95% 12.93% 16.44% 10.75% 11.53% 5.70%
1.53 1.76 2.52 1.37 2.14 1.54 6.39 3.95 6.96 2.86 3.46 2.40 3.24
Interest 0.02 0.29 0.22 0.21 0.31 0.25 0.34 0.79 0.80 0.88 0.61 0.61 1.09
Depreciation 1.69 1.74 1.72 1.64 1.56 1.54 1.45 1.43 1.43 1.51 1.61 1.67 1.61
Profit before tax 2.55 10.43 10.77 2.36 4.81 1.68 13.94 5.24 11.32 11.96 7.67 6.90 4.28
Tax % 23.14% 25.60% 25.53% 38.14% 15.59% 25.60% 28.34% 27.29% 17.93% 25.67% 27.51% 26.52% 28.27%
1.96 7.76 8.02 1.46 4.06 1.25 9.99 3.81 9.29 8.89 5.56 5.07 3.07
EPS in Rs 3.42 13.54 14.00 2.55 7.03 2.16 17.30 6.60 16.09 15.39 9.63 8.78 5.32
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
95 114 119 125 111 136 220 226 204 212 218 254
86 102 108 114 104 123 189 196 179 183 196 226
Operating Profit 9 12 11 10 7 13 30 30 25 29 22 28
OPM % 10% 10% 9% 8% 6% 10% 14% 13% 12% 14% 10% 11%
3 -1 4 5 8 7 13 11 9 7 19 12
Interest 1 1 2 1 1 1 1 1 1 1 3 3
Depreciation 3 3 4 4 6 6 6 6 6 7 6 6
Profit before tax 8 6 9 9 8 14 36 35 27 28 32 31
Tax % 10% -3% 15% 31% 7% 27% 37% 25% 25% 25% 24% 27%
7 7 7 6 7 10 23 26 20 21 24 23
EPS in Rs 12.93 11.43 12.98 11.26 12.88 17.63 39.39 45.90 35.27 36.89 42.15 39.12
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 2% 3%
Compounded Sales Growth
10 Years: 8%
5 Years: 3%
3 Years: 8%
TTM: 17%
Compounded Profit Growth
10 Years: 9%
5 Years: 0%
3 Years: 4%
TTM: 14%
Stock Price CAGR
10 Years: %
5 Years: 49%
3 Years: 48%
1 Year: 316%
Return on Equity
10 Years: 15%
5 Years: 14%
3 Years: 12%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 6 6 6 6 6 6 6 6 6 6 6 6
Reserves 30 37 44 51 58 69 91 117 138 160 185 208
14 21 16 19 6 9 5 1 12 15 46 83
26 37 50 44 40 50 60 68 40 37 71 91
Total Liabilities 76 101 116 120 111 133 161 192 196 218 308 387
23 29 29 35 31 34 35 33 45 41 36 39
CWIP 0 0 0 0 0 0 1 12 0 1 0 0
Investments 0 0 0 0 1 1 2 0 42 16 38 49
53 72 87 85 79 99 123 147 110 160 233 299
Total Assets 76 101 116 120 111 133 161 192 196 218 308 387

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-2 5 0 -2 6 20 14 22 -22 -12 -23
-5 -8 0 -2 -8 -9 -13 -41 22 -14 -16
7 6 0 -8 4 -4 -3 11 2 29 34
Net Cash Flow 1 2 0 -11 2 7 -1 -8 2 3 -5

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 76 126 179 129 144 158 109 132 122 126 188 201
Inventory Days 111 70 55 62 69 60 55 69 61 56 100 125
Days Payable 95 119 188 171 167 110 82 106 71 60 127 123
Cash Conversion Cycle 91 77 47 20 46 108 82 95 111 122 161 204
Working Capital Days 74 67 72 45 65 95 81 97 118 159 163 182
ROCE % 21% 18% 17% 15% 12% 19% 40% 32% 20% 18% 14%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
74.42% 74.42% 74.42% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.84% 73.27%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
25.57% 25.57% 25.57% 26.15% 26.15% 26.16% 26.16% 26.15% 26.16% 26.15% 26.15% 26.72%
No. of Shareholders 3,1222,9122,8052,7962,7652,7002,6082,5152,4852,4812,3972,497

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents